In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline

In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline

Source: 
Enpoints
snippet: 

Dewpoint Therapeutics has lined up another Big Pharma partner, this time Danish drugmaker Novo Nordisk, in a bet that its strategy of going after molecular clusters known as condensates could have an impact on insulin resistance and diabetic complications.